Table 2.
Adverse events after treatment in whole population.
| Adverse events | Any grade |
Grade ≥3 |
||
|---|---|---|---|---|
| TACE-ICI-VEGF (n = 802) | ICI-VEGF (n = 442) | TACE-ICI-VEGF (n = 802) | ICI-VEGF (n = 442) | |
| Abdominal pain | 200 (24.9) | 8 (1.8) | 44 (5.5) | 1 (0.2) |
| Pyrexia | 193 (24.1) | 22 (5.0) | 8 (1.0) | 3 (0.7) |
| Increased ALT | 158 (19.7) | 61 (13.8) | 23 (2.9) | 9 (2.0) |
| Increased AST | 151 (18.8) | 60 (13.6) | 22 (2.7) | 10 (2.3) |
| Hypertension | 135 (16.8) | 87 (19.7) | 26 (3.2) | 19 (4.3) |
| Pain | 115 (14.3) | 15 (3.4) | 3 (0.4) | 0 |
| HFSR | 96 (12.0) | 41 (9.3) | 15 (1.9) | 4 (0.9) |
| Fatigue | 106 (13.2) | 64 (14.5) | 13 (1.6) | 5 (1.1) |
| Nausea | 97 (12.1) | 22 (5.0) | 2 (0.2) | 0 |
| Vomiting | 92 (11.5) | 10 (2.3) | 2 (0.2) | 1 (0.2) |
| Elevated bilirubin | 76 (9.5) | 42 (9.5) | 14 (1.7) | 11 (2.5) |
| Diarrhea | 75 (9.4) | 50 (11.3) | 10 (1.2) | 8 (1.8) |
| Rash | 73 (9.1) | 52 (11.8) | 8 (1.0) | 4 (0.9) |
| Proteinuria | 52 (6.5) | 39 (8.8) | 6 (0.7) | 3 (0.7) |
| Anorexia | 62 (7.7) | 41 (9.3) | 4 (0.5) | 2 (0.5) |
| Hypothyroidism | 45 (5.6) | 28 (6.3) | 2 (0.2) | 0 |
| RCCEP | 41 (5.1) | 12 (2.7) | 3 (0.4) | 0 |
| Thrombocytopenia | 36 (4.5) | 41 (9.3) | 8 (1.0) | 8 (1.8) |
| Gastrointestinal hemorrhage | 23 (2.9) | 18 (4.1) | 8 (1.0) | 9 (2.0) |
| Decreased WBC count | 21 (2.6) | 13 (2.9) | 3 (0.4) | 1 (0.2) |
| Abdominal distension | 18 (2.2) | 5 (1.1) | 1 (0.1) | 0 |
| Ascites | 17 (2.1) | 17 (3.8) | 1 (0.1) | 1 (0.2) |
| Pruritus | 11 (1.4) | 7 (1.6) | 2 (0.2) | 0 |
| Pneumonitis | 11 (1.4) | 7 (1.6) | 4 (0.5) | 2 (0.5) |
| Infusion-related reaction | 5 (0.6) | 0 | 0 | 0 |
| Weight decrease | 4 (0.5) | 2 (0.5) | 0 | 0 |
| Constipation | 3 (0.4) | 3 (0.7) | 0 | 0 |
TACE-ICI-VEGF, TACE with ICIs plus anti-VEGF antibody/TKIs; ICI-VEGF, ICIs plus anti-VEGF antibody/TKIs; TACE, transarterial chemoembolization; ICIs, immune checkpoint inhibitors; VEGF, vascular endothelial growth factor; TKIs, tyrosine kinase inhibitors; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HFSR, hand-foot skin reaction; RCCEP, reactive cutaneous capillary endothelial proliferation; WBC, white blood cell.